Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma

Jin Zhou1 Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, [email protected]

Sheng Han2 Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, [email protected];3 Key Laboratory of Liver Transplantation, Chinese Academy of Medical Science, Beijing, China, [email protected]

Weichun Qian4 Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

Yuanyuan Gu1 Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, [email protected]

Xiangcheng Li2 Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, [email protected];3 Key Laboratory of Liver Transplantation, Chinese Academy of Medical Science, Beijing, China, [email protected]Correspondence[email protected]

Kunxing Yang1 Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, [email protected]Correspondence[email protected]

Pages 4451-4459 | Published online: 31 Jul 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GomesMAPriolliDGTralhaoJGBotelhoMFHepatocellular carcinoma: epidemiology, biology, diagnosis, and therapiesRev Assoc Med Bras (1992)201359551452424041910
PubMed Web of Science ®Google Scholar
HerszenyiLTulassayZEpidemiology of gastrointestinal and liver tumorsEur Rev Med Pharmacol Sci201014424925820496531
PubMed Web of Science ®Google Scholar
WangJHeXDYaoNLiangWJZhangYCA meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinomaCan J Gastroenterol201327635136323781519
PubMed Web of Science ®Google Scholar
ChanDLMorrisDLChuaTCClinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma – a systematic reviewSurg Oncol2013222e23e3023535302
PubMed Web of Science ®Google Scholar
GluerAMCoccoNLaurenceJMSystematic review of actual 10-year survival following resection for hepatocellular carcinomaHPB (Oxford)201214528529022487065
PubMed Web of Science ®Google Scholar
ZhouXDRecurrence and metastasis of hepatocellular carcinoma: progress and prospectsHepatobiliary Pancreat Dis Int200211354114607620
PubMedGoogle Scholar
WangYDaiWChuXYangBZhaoMSunYMetformin inhibits lung cancer cells proliferation through repressing microRNA-222Biotechnol Lett201335122013201923974492
PubMed Web of Science ®Google Scholar
QuHYangXMetformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cellsCell Biochem Biophys201571293193625326336
PubMed Web of Science ®Google Scholar
HsiehSCTsaiJPYangSFTangMJHsiehYHMetformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expressionAmino Acids201446122809282225245054
PubMed Web of Science ®Google Scholar
YangXSunDTianYLingSWangLMetformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bc12 expressionTumour Biol20153642957296425492486
PubMedGoogle Scholar
ZhangHHZhangYChengYNMetformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivoMol Carcinog2018571445628833603
PubMed Web of Science ®Google Scholar
BartelDPMicroRNAs: genomics, biogenesis, mechanism, and functionCell2004116228129714744438
PubMed Web of Science ®Google Scholar
LeeDYDengZWangCHYangBBMicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expressionProc Natl Acad Sci U S A200710451203502035518077375
PubMed Web of Science ®Google Scholar
UrbichCKuehbacherADimmelerSRole of microRNAs in vascular diseases, inflammation, and angiogenesisCardiovasc Res200879458158818550634
PubMed Web of Science ®Google Scholar
SongGSharmaADRollGRMicroRNAs control hepatocyte proliferation during liver regenerationHepatology20105151735174320432256
PubMed Web of Science ®Google Scholar
MiyoshiHKatoKIwamaHEffect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivoInt J Oncol201445132233224806290
PubMed Web of Science ®Google Scholar
PangRWPoonRTFrom molecular biology to targeted therapies for hepatocellular carcinoma: the future is nowOncology200772Suppl 1304418087180
PubMed Web of Science ®Google Scholar
MoralesDRMorrisADMetformin in cancer treatment and preventionAnnu Rev Med201566172925386929
PubMed Web of Science ®Google Scholar
DoMTKimHGChoiJHJeongHGMetformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agentsFree Radic Biol Med201474213424970682
PubMed Web of Science ®Google Scholar
JaraJALopez-MunozRMetformin and cancer: between the bioenergetic disturbances and the antifolate activityPharmacol Res201510110210826277279
PubMed Web of Science ®Google Scholar
ZhouJYXuBLiLA new role for an old drug: metformin targets microRNAs in treating diabetes and cancerDrug Dev Res201576626326926936407
PubMed Web of Science ®Google Scholar
Nangia-MakkerPYuYVasudevanAMetformin: a potential therapeutic agent for recurrent colon cancerPLoS One201491e8436924465408
PubMed Web of Science ®Google Scholar
Wahdan-AlaswadRSCochraneDRSpoelstraNSMetformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193bHorm Cancer20145637438925213330
PubMed Web of Science ®Google Scholar
LiWYuanYHuangLQiaoMZhangYMetformin alters the expression profiles of microRNAs in human pancreatic cancer cellsDiabetes Res Clin Pract201296218719522245693
PubMed Web of Science ®Google Scholar
LiJHernandaPYBramerWMPeppelenboschMPvan LuijkJPanQAnti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysisPLoS One2015106e012796726030161
PubMed Web of Science ®Google Scholar
SaitoTChibaTYukiKMetformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cellsPLoS One201387e7001023922888
PubMed Web of Science ®Google Scholar
AnJLiuJLiuLA genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese populationPLoS One201494e9370724751683
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date